# Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects

> **NCT00684710** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 56 (estimated)

## Conditions studied

- Alzheimer Disease
- Healthy

## Interventions

- **DRUG:** PAZ-417
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00684710
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2009-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684710, "Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00684710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*